Mercury Biopharmaceutical Corporation (TPEX: 6932)

Market Cap	5.43B
Revenue (ttm)	5.75M
Net Income (ttm)	-43.41M
Shares Out	417.45M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,001
Open	13.20
Previous Close	13.15
Day's Range	12.80 - 13.30
52-Week Range	10.10 - 20.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Mercury Biopharmaceutical

Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects. It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6932

Financial Performance

In 2023, Mercury Biopharmaceutical's revenue was 1.03 million, a decrease of -61.46% compared to the previous year's 2.68 million. Losses were -43.82 million, 40.2% more than in 2022.